公开(公告)号：WO2006055371A8

公开(公告)日：2006-12-07

申请号：PCT/US2005040598

申请日：2005-11-08

Applicant: ALEXION PHARMA INC ,  MARUYAMA TOSHIAKI ,  OLTEAN DANIELA ,  YANTIRI-WERNIMONT FERDA ,  XIN HONG ,  SIVA AMARA ,  BOWDISH KATHERINE S

Inventor： MARUYAMA TOSHIAKI ,  OLTEAN DANIELA ,  YANTIRI-WERNIMONT FERDA ,  XIN HONG ,  SIVA AMARA ,  BOWDISH KATHERINE S

IPC: G01N33/53 ,  G01N33/569 ,  G01N33/68

CPC classification number: C40B30/04 ,  C07K16/00 ,  G01N33/6878

Abstract: High throughput screening of antibody candidates to identify those having desired functional effects on target cells is provided by contacting antibody candidates with plated target cells in the presence of a secondary, anti-antibody antibody.

Abstract translation: 通过在二级抗体抗体的存在下使抗体候选物与电镀的靶细胞接触来提供抗体候选物的高通量筛选以鉴定对靶细胞具有期望的功能作用的抗体候选物。

公开(公告)号：WO2006073748A2

公开(公告)日：2006-07-13

申请号：PCT/US2005045706

申请日：2005-12-16

Applicant: ALEXION PHARMA INC ,  BOWDISH KATHERINE S ,  KRETZ-ROMMEL ANKE ,  DAKAPPAGARI NAVEEN

Inventor： BOWDISH KATHERINE S ,  KRETZ-ROMMEL ANKE ,  DAKAPPAGARI NAVEEN

IPC: C07K16/28 ,  A61K20060101 ,  A61K39/395 ,  A61K39/40 ,  A61K39/42 ,  A61P35/00 ,  C07K16/00 ,  C07K16/10 ,  C07K16/46 ,  C12N5/06 ,  C12N5/08

CPC classification number: C07K16/2851 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2319/30 ,  G01N33/574

Abstract: Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells, Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity.

Abstract translation: 抗原呈递细胞的抗体可用于干扰抗原呈递细胞和免疫细胞（包括T细胞）的相互作用。肽可以与所述抗体连接，从而产生对这些肽的免疫应答。 与抗体连接的肽优选与自身免疫相关。

公开(公告)号：WO2004050017A3

公开(公告)日：2005-01-13

申请号：PCT/US0336894

申请日：2003-11-17

Applicant: ALEXION PHARMA INC

Inventor： BOWDISH KATHERINE S ,  FREDERICKSON SHANA ,  RENSHAW MARK

IPC: C07K14/505 ,  C07K14/52 ,  C07K16/00 ,  C07K16/12 ,  C07K16/18 ,  C07K16/46 ,  C12N1/21 ,  C12N15/13 ,  C07H21/04 ,  A61K39/395 ,  C12N15/00 ,  C12N15/63

CPC classification number: C07K14/505 ,  A61K2039/505 ,  C07K14/524 ,  C07K16/00 ,  C07K16/005 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/46 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2319/00 ,  C07K2319/30

Abstract: Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

Abstract translation: 描述了具有替换或与生物活性肽融合的至少两个CDR区的抗体或其片段。 含有此类抗体或其片段的组合物可用于治疗和诊断方式。

公开(公告)号：WO03048321A3

公开(公告)日：2003-10-16

申请号：PCT/US0238450

申请日：2002-12-03

Applicant: ALEXION PHARMA INC ,  ROTHER RUSSELL ,  WU DAYANG

Inventor： ROTHER RUSSELL ,  WU DAYANG

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/46 ,  C12P21/08 ,  C12N15/00

CPC classification number: C07K16/00 ,  C07K2317/565

Abstract: Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and nonhuman CDRs.

Abstract translation: 提供杂交抗体和/或杂交抗体片段及其制备方法。 在一个实施方案中，杂合抗体和/或杂合抗体片段含有含有来自至少两种抗体的两个或更多个框架区的重和/或可变区。 在另一个实施方案中，框架区域中的至少两个被分类在相同的种系基因家族中。 在一个实施方案中，将至少两个框架区域分类在相同的种系基因家族成员中。 杂合抗体或杂合抗体片段可以含有人框架区和非人CDR。

公开(公告)号：WO0246238A3

公开(公告)日：2003-07-10

申请号：PCT/US0147656

申请日：2001-12-05

Applicant: ALEXION PHARMA INC

Inventor： BOWDISH KATHERINE S ,  BARBAS-FREDERICKSON SHANA ,  RENSHAW MARK

IPC: A61K39/00 ,  C07K14/505 ,  C07K14/52 ,  C07K16/00 ,  C07K16/12 ,  C07K16/18 ,  C07K16/46 ,  C12N1/21 ,  C12N15/13 ,  C07K19/00 ,  A61K39/395 ,  C12N15/62 ,  C12N15/70 ,  G01N33/50 ,  G01N33/573

CPC classification number: C07K14/505 ,  A61K39/00 ,  A61K39/40 ,  A61K2039/505 ,  C07K14/524 ,  C07K16/00 ,  C07K16/005 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/46 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2318/10 ,  C07K2319/00 ,  C07K2319/036 ,  C07K2319/30 ,  C07K2319/75 ,  C12N5/0641 ,  C12N2501/14 ,  C12N2506/11

Abstract: Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.

Abstract translation: 描述了具有替换或与生物活性肽融合的CDR区的抗体或其片段。 侧翼序列可以任选地在肽的羧基末端和氨基末端的一个或两个连接，与相邻构架区共价结合。 含有此类抗体或其片段的组合物可用于治疗和诊断方式。

公开(公告)号：WO02059280A3

公开(公告)日：2003-04-10

申请号：PCT/US0147931

申请日：2001-12-10

Applicant: ALEXION PHARMA INC ,  BOWDISH KATHERINE S ,  MCWHIRTER JOHN

Inventor： BOWDISH KATHERINE S ,  MCWHIRTER JOHN

IPC: C12N5/06 ,  C07K16/30 ,  C12N5/08 ,  G01N33/50 ,  G01N33/569 ,  G01N33/574 ,  G01N33/577

CPC classification number: C07K16/3061 ,  C07K16/3076 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/5005 ,  G01N33/5011 ,  G01N33/56972 ,  G01N33/57426 ,  G01N2333/70596 ,  G01N2500/20

Abstract: A CLL line, CLL-AAT, and the preparation and characterization of antibodies using said cell line is disclosed.

Abstract translation: 公开了CLL系，CLL-AAT以及使用所述细胞系的抗体的制备和表征。

公开(公告)号：WO2013137912A3

公开(公告)日：2014-05-01

申请号：PCT/US2012029499

申请日：2012-03-16

Applicant: ALEXION PHARMA INC ,  BELL LEONARD

Inventor： BELL LEONARD

IPC: G06F19/00 ,  A61K31/00 ,  G06F19/28

CPC classification number: G06Q50/22 ,  F04C2270/041 ,  G01N33/50

Abstract: This disclosure relates to methods of authorizing distribution of complement-inhibiting drugs to patients who have a complement-associated disorder in a manner to ensure that the patients are aware of the possible dangers of discontinuing treatment with the drugs. A database is prepared comprising patient information including experiencing adverse clinical events after discontinuing the drug treatment. The information in the database is collected and may be reported. The patients are given a warning as to adverse events that may occur if treatment with the complement inhibiting drugs is discontinued.

Abstract translation: 本公开涉及授权补体抑制药物分布给患有补体相关障碍的患者的方法，以确保患者了解可能的药物停止治疗的危险。 制备数据库，其包括患者信息，包括在停止药物治疗后经历不利的临床事件。 收集数据库中的信息并报告。 给予患者关于如果停用补体抑制药物治疗可能发生的不良事件的警告。

公开(公告)号：WO2004078938A3

公开(公告)日：2008-11-06

申请号：PCT/US2004006577

申请日：2004-03-04

Applicant: ALEXION PHARMA INC

Inventor： BOWDISH KATHERINE S ,  MCWHIRTER JOHN ,  KRETZ-ROMMEL ANKE

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/30 ,  C12N5/08 ,  G01N33/50 ,  G01N33/567 ,  G01N33/569 ,  G01N33/574

CPC classification number: C07K16/3061 ,  C07K16/3076 ,  C07K2317/565 ,  C07K2317/622 ,  G01N33/5005 ,  G01N33/5011 ,  G01N33/56972 ,  G01N33/57426 ,  G01N2333/70596 ,  G01N2500/20

Abstract: Methods for administering polypeptides, including antibodies, capable of binding to OX-2/CD200 and/or an OX-2/CD200 receptor are disclosed. These polypeptides are useful in treating disease states characterized by upregulated levels of OX-2/CD200, including cancer and CLL.

Abstract translation: 公开了用于施用能够结合OX-2 / CD200和/或OX-2 / CD200受体的多肽（包括抗体）的方法。 这些多肽可用于治疗以上调OX-2 / CD200水平为特征的疾病状态，包括癌症和CLL。

公开(公告)号：WO2008069889A9

公开(公告)日：2008-09-18

申请号：PCT/US2007023623

申请日：2007-11-08

Applicant: ALEXION PHARMA INC ,  BELL LEONARD ,  ROTHER RUSSELL P

Inventor： BELL LEONARD ,  ROTHER RUSSELL P

IPC: A61K39/395 ,  A61P7/02 ,  A61P7/06 ,  C12Q1/06

CPC classification number: C07K16/18 ,  A61K2039/505

Abstract: Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.

Abstract translation: 使用结合或阻断一种或多种补体成分（例如补体抑制性抗体）的产生和/或活性的化合物治疗阵发性夜间血红蛋白尿或其他溶血性疾病。

公开(公告)号：WO2007103134A3

公开(公告)日：2008-09-12

申请号：PCT/US2007005290

申请日：2007-03-02

Applicant: ALEXION PHARMA INC ,  ROTHER RUSSELL P ,  WANG HAO ,  ZHONG ZHEN

Inventor： ROTHER RUSSELL P ,  WANG HAO ,  ZHONG ZHEN

IPC: A61K31/00 ,  A61K31/16 ,  A61K31/365 ,  A61K31/573 ,  A61K38/00 ,  A61K38/13 ,  A61K39/395 ,  A61K45/06 ,  A61P37/06

CPC classification number: C07K16/18 ,  A61K31/16 ,  A61K31/365 ,  A61K31/573 ,  A61K38/13 ,  A61K2039/505

Abstract: Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allograft recipient an inhibitor of complement activity together with one or more immunosuppressants and/or immunosuppressive methods. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.

Abstract translation: 提出了延长移植细胞，组织或器官存活的方法。 这些方法涉及向同种异体移植受体施用补体活性的抑制剂以及一种或多种免疫抑制剂和/或免疫抑制方法。 补体活性抑制剂长期施用。 已经确定了这些方法以帮助预防同种异体移植物的慢性排斥反应。 这些方法可以另外用于接受者已经被同化异体移植或同种异体移植物与受体之间存在ABO不匹配的情况。